Jaguar Health Addresses Nasdaq Publicly Held Shares Deficiency After Delisting Notice

summarizeSummary

Jaguar Health received a Nasdaq delisting notice for insufficient publicly held shares but quickly took action by exercising warrants to regain compliance, though the $1.00 bid price issue remains.

check_boxKey Events · Corporate Governance and Compliance · JAGX

• Nasdaq Delisting Notice Received

  On May 1, 2026, Nasdaq notified Jaguar Health of non-compliance with the minimum 500,000 publicly held shares requirement, triggered by the 1-for-35 reverse stock split on April 30, 2026.

• Publicly Held Shares Deficiency Addressed

  The company facilitated the exercise of pre-funded warrants on May 4, 2026, increasing publicly held shares to 513,939, and is awaiting Nasdaq's formal confirmation of compliance.

• Ongoing Bid Price Non-Compliance

  Jaguar Health remains non-compliant with Nasdaq's minimum $1.00 bid price requirement, which must be cured after the publicly held shares issue is resolved.

auto_awesomeAnalysis · JAGX · Life Sciences

This 8-K details Jaguar Health's immediate response to a Nasdaq delisting notice received on May 1, 2026, for failing to meet the minimum 500,000 publicly held shares requirement following its recent 1-for-35 reverse stock split. The company quickly addressed this by facilitating the exercise of pre-funded warrants on May 4, 2026, increasing its publicly held shares to 513,939. While this action appears to cure one delisting threat, the company still needs to regain compliance with Nasdaq's $1.00 minimum bid price rule. This event highlights the company's ongoing struggle to maintain its Nasdaq listing amidst severe financial distress and previous warnings.